Please note that the ANZCTR website will be unavailable from 9am until 9.30am (AEST) on Monday 22nd July for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00441441




Registration number
NCT00441441
Ethics application status
Date submitted
28/02/2007
Date registered
1/03/2007
Date last updated
16/12/2016

Titles & IDs
Public title
A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma
Scientific title
A Randomized, Double-blind, Parallel Group Study Evaluating the Safety of Fluticasone Propionate/Salmeterol 100/50mcg HFA (2 Inhalations of 50/25mcg) Twice Daily Compared With Fluticasone Propionate 100mcg HFA (2 Inhalations of 50mcg) Twice Daily in Subjects 4-11 Years of Age With Persistent Asthma
Secondary ID [1] 0 0
SFA106484
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Asthma 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Asthma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - fluticasone propionate
Treatment: Drugs - fluticasone propionate/salmeterol

Experimental: Fluticasone propionate/salmeterol 100/50 HFA - Fluticasone propionate/salmeterol 100/50 HFA (2 inhalations of 50/25mcg), twice daily (strengths are ex-valve) and a placebo HFA inhaler matching the fluticasone propionate 100mcg HFA inhaler (2 inhalations) twice daily

Experimental: Fluticasone propionate 100mcg HFA - Fluticasone propionate 100mcg HFA (2 inhalations of 50mcg), twice daily (strengths are ex-valve) and a placebo HFA inhaler matching the fluticasone propionate/salmeterol 100/50 HFA inhaler (2 inhalations ) twice daily


Treatment: Drugs: fluticasone propionate
fluticasone propionate 100mcg HFA

Treatment: Drugs: fluticasone propionate/salmeterol
fluticasone propionate/salmeterol 100/50mcg HFA

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Possible Drug-Related Adverse Events - Adverse Events reported by the Investigator and judged by the Investigator to be possibly related to study drug, categorized by the Medical Dictionary for Regulatory Activities (MeDRA), were reported. ECG, electrocardiogram. QTc (corrected QT interval) and QT represent intervals on an ECG.
Timepoint [1] 0 0
Treatment period (weeks 1-12) and Post Treatment (=1 day after last time study drug)
Primary outcome [2] 0 0
Investigator Evaluations of Electrocardiogram (ECG) Results - ECGs were transmitted to an independent cardiologist who was responsible for providing interpretation of the ECG as either normal or abnormal (based on personal assessment). The investigator was then responsible for determining the clinical significance of the abnormal ECG in the context of the participants' history and clinical presentation. An abnormal, clinically significant ECG included, but was not limited to: prolonged QT interval, ischemic changes, ventricular hypertrophy, intraventricular conduction abnormalities, and clinically significant arrhythmias. PD, premature discontinuation.
Timepoint [2] 0 0
Baseline and Week 12
Primary outcome [3] 0 0
Clinically Significant Unfavorable ECGs at Week 12 - Post-randomization ECGs categorized by the primary investigator as no change, significant change (favorable), significant change (unfavorable) from the ECG performed at Visit 1 (Baseline) are presented. Significant change (favorable) includes any ECG that improved from baseline, whereas significant change (unfavorable) includes any ECG that worsened from baseline. Clinical significance is determined by the primary investigator.
Timepoint [3] 0 0
Baseline, Week 12
Primary outcome [4] 0 0
ECG Measures - Heart Rate - The range of heart rates for this study was between 49-144 beats per minute
Timepoint [4] 0 0
Baseline and Week 12
Primary outcome [5] 0 0
ECG Measures - QT Interval - Fridericia's formula QTc interval=QT interval/cubed root of the R-R interval. The Bazett's formula QTc=QT/squared root of the R-R interval.
Timepoint [5] 0 0
Baseline and Week 12
Primary outcome [6] 0 0
Cardiovascular Adverse Events Reported During Treatment Period - Cardiovascular Adverse Events, as categorized by the Medical Dictionary for Regulatory Activities (MeDRA), reported during Treatment Period. The Adverse Events were identified in any ECG interpretation by a central reader (Cardiologist) for any ECG obtained after the first treatment dose and were then reported by the Primary Investigator as an Adverse Event. Please see the category titles for a list of candidate cardiovascular adverse events.
Timepoint [6] 0 0
12-Week Treatment Period
Primary outcome [7] 0 0
Cardiovascular Adverse Events Reported During the Post-Treatment Period - Cardiovascular Adverse Events, as categorized by the Medical Dictionary for Regulatory Activities (MeDRA), reported during Post-treatment period, defined as 1 day after last dose of study drug. The Adverse Events were identified in any ECG interpretation by a central reader (Cardiologist) for any ECG obtained after the first treatment dose and were then reported by the Primary Investigator as an Adverse Event.
Timepoint [7] 0 0
5 Days after Week 12
Primary outcome [8] 0 0
Asthma Exacerbations: Worsening of Asthma Requiring Emergency Intervention, Hospitalization, or Treatment With Asthma Medications Prohibited by the Protocols - The Primary Investigator determined the severity of the exacerbation based on the participant's clinical presentation and the investigator's understanding of the disease, the participant, and his or her clinical experiences. The severity of the exacerbation was not defined in the protocol. Mild: Usually treated at home. Prompt relief with inhaled short-acting beta2 agonist. Possible short course of oral systemic corticosteroids. Moderate: Usually requires office or emergency department visit. Relief with frequent inhaled short-acting beta2 agonist. Oral systemic corticosteroids; some symptoms last for 1-2 days after treatment begins. Severe: Usually requires emergency department visit and likely hospitalization. Partial relief with frequent inhaled short-acting beta2 agonist. Oral systemic corticosteroids; some symptoms last for more than 3 days after treatment begins. Adjunctive therapies are helpful.
Timepoint [8] 0 0
Treatment period (weeks 1-12)
Primary outcome [9] 0 0
Number of Participants With the Indicated Levels of 24-hour Urinary Cortisol Excretion - "Abnormal high cortisol excretion" and "Abnormal low cortisol excretion" are defined as above the upper limit of normal and below the lower limit of normal, respectively. The normal range for cortisol levels vary by age and gender. An abnormality is defined as a value of 24-hour urinary cortisol excretion that is outside the normal range. The normal range for 24-hour urinary cortisol excretion was provided by the central laboratory.
Timepoint [9] 0 0
Baseline and week 12
Primary outcome [10] 0 0
Geometric Mean Values of 24-hour Urinary Cortisol Excretion at Baseline and Week 12 - Normal range for Cortisol levels vary by age and gender. Geometric mean is the product of the values taken to the Nth root, where N is the number of values in the set of values.
Timepoint [10] 0 0
Baseline and Week 12
Primary outcome [11] 0 0
Geometric Mean Ratio for Week12:Baseline for 24-hour Urinary Cortisol Excretion - Normal range for Cortisol levels vary by age and gender. The data provided are a direct calculation of the Week 12 geometric mean divided by the baseline value, nanomoles per 24 hours (nmol/24 hrs).
Timepoint [11] 0 0
Baseline and Week 12
Primary outcome [12] 0 0
Number of Participants With the Indicated Levels of 24 Hour Urinary Cortisol Excretion by Spacer Use - AeroChamber Plus spacers were provided for participants who demonstrated the inability to coordinate the use of an Meter Dose Inhaler at Visit 1. AeroChamber Plus spacer delivers 22% more medication than the original AeroChamber and is available in three mask sizes and without a mask. "Abnormal high cortisol excretion" and "Abnormal low cortisol excretion" are defined as above the upper limit of normal and below the lower limit of normal, respectively. An abnormality is defined as a value of 24-hour urinary cortisol excretion that is outside the normal range. The normal range for 24-hour urinary cortisol excretion was provided by the central laboratory.
Timepoint [12] 0 0
Baseline and Week 12
Primary outcome [13] 0 0
Geometric Mean Values of 24 Hour Urinary Cortisol Excretion by Spacer Use at Baseline and Week 12 - AeroChamber Plus spacers were provided for participants who demonstrated the inability to coordinate the use of an Meter Dose Inhaler at Visit 1. AeroChamber Plus spacer delivers 22% more medication than the original AeroChamber and is available in three mask sizes and without a mask. Geometric mean is the product of the values taken to the Nth root, where N is the number of values in the set of values.
Timepoint [13] 0 0
Baseline and Week 12
Primary outcome [14] 0 0
Geometric Mean Ratio for Week12: Baseline for 24 Hour Urinary Cortisol Excretion by Spacer Use - AeroChamber Plus spacers were provided for participants who demonstrated the inability to coordinate the use of an Meter Dose Inhaler at Visit 1. AeroChamber Plus spacer delivers 22% more medication than the original AeroChamber and is available in three mask sizes and without a mask. The data provided are a direct calculation of the Week 12 geometric mean divided by the baseline value, nanomoles per 24 hours (nmol/24 hrs).
Timepoint [14] 0 0
Baseline and Week 12
Secondary outcome [1] 0 0
Clinic Morning (AM) Forced Expiratory Volume in Participants 6-11 Years - FEV1 (Forced Expiratory Volume in 1 second) is the volume of air that can be forced out in one second, after taking a deep breath. FEV1 is measured using a spirometer and obtaining "best effort" from 3 to 8 measurements. Week 12 is the measure taken at Week 12.
Timepoint [1] 0 0
Baseline and week 12
Secondary outcome [2] 0 0
AM Peak Expiratory Flow - The peak expiratory flow (PEF) rate measures how fast a person can exhale air. It is used to compare to normal flow rates to predict obstruction and disease. The average PEF for a child or adolescent whose height is 43 inches is 147 Liters/minute (L/min), whose height is 66 inches is 454 L/min. Triplicate measurements taken for the best effort recorded.
Timepoint [2] 0 0
Baseline and 12-Week Treatment Period
Secondary outcome [3] 0 0
Asthma Symptom Scores - Each morning prior dosing or PEF, self-scored based on past 24 hours: 0=No symptoms, 1=Symptoms for one short period, 2=Symptoms for two or more short periods, 3=Frequent Symptoms which did not affect activities of daily living (ADL), 4=Frequent.
Timepoint [3] 0 0
Baseline and 12-Week Treatment Period
Secondary outcome [4] 0 0
Percentage of Symptom Free Days - Percentage of number of days without asthma symptoms based on Asthma Symptom Scores. Each morning prior to dosing or PEF, asthma symptoms were self-scored based on the past 24 hours: 0=no symptoms, 1=symptoms for one short period, 2=symptoms for two or more short periods, 3=frequent symptoms that did not affect activities of daily living (ADL), 4=frequent .
Timepoint [4] 0 0
Baseline and 12-Week Treatment Period
Secondary outcome [5] 0 0
Albuterol Use - Albuterol inhalation aerosol was used as a rescue or prophylactic and recorded daily by subject or caregiver. The number of puffs of albuterol over the previous 24 hour period prior to dosing was recorded.
Timepoint [5] 0 0
Baseline and 12-Week Treatment Period
Secondary outcome [6] 0 0
Percent of Albuterol-free Days - Percentage of days when Albuterol use was unnecessary based on daily record and symptom free days.
Timepoint [6] 0 0
Baseline and 12-Week Treatment Period

Eligibility
Key inclusion criteria
Inclusion criteria:

- Must have asthma.

- Must be currently taking an inhaled corticosteroid.

- Must be able to attend 7 clinic visits, of which up to 3 will be in the morning, and
have lung function tests that are at least 60% of normal (AM FEV1 or PEF).

- Have a historical or current FEV1 or PEF reversibility of >=12%.
Minimum age
4 Years
Maximum age
11 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

- Has ever had life-threatening asthma (for example respiratory arrest, mechanical
ventilation).

- Has a current ear or respiratory tract infection.

- Has ever had any other major illnesses (such as cystic fibrosis, heart problems,
tuberculosis).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC,WA
Recruitment hospital [1] 0 0
GSK Investigational Site - Clayton
Recruitment hospital [2] 0 0
GSK Investigational Site - Parkville
Recruitment hospital [3] 0 0
GSK Investigational Site - Subiaco
Recruitment postcode(s) [1] 0 0
3168 - Clayton
Recruitment postcode(s) [2] 0 0
3052 - Parkville
Recruitment postcode(s) [3] 0 0
6001 - Subiaco
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Michigan
Country [6] 0 0
United States of America
State/province [6] 0 0
New York
Country [7] 0 0
United States of America
State/province [7] 0 0
North Carolina
Country [8] 0 0
United States of America
State/province [8] 0 0
Ohio
Country [9] 0 0
United States of America
State/province [9] 0 0
Oklahoma
Country [10] 0 0
United States of America
State/province [10] 0 0
Oregon
Country [11] 0 0
United States of America
State/province [11] 0 0
Pennsylvania
Country [12] 0 0
United States of America
State/province [12] 0 0
South Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Tennessee
Country [14] 0 0
United States of America
State/province [14] 0 0
Vermont
Country [15] 0 0
Canada
State/province [15] 0 0
Newfoundland and Labrador
Country [16] 0 0
Canada
State/province [16] 0 0
Ontario
Country [17] 0 0
Chile
State/province [17] 0 0
Región Metro De Santiago
Country [18] 0 0
Chile
State/province [18] 0 0
Valparaíso
Country [19] 0 0
Chile
State/province [19] 0 0
Santiago
Country [20] 0 0
Costa Rica
State/province [20] 0 0
San Jose
Country [21] 0 0
Germany
State/province [21] 0 0
Nordrhein-Westfalen
Country [22] 0 0
Germany
State/province [22] 0 0
Rheinland-Pfalz
Country [23] 0 0
Germany
State/province [23] 0 0
Schleswig-Holstein
Country [24] 0 0
Latvia
State/province [24] 0 0
Ogre
Country [25] 0 0
Latvia
State/province [25] 0 0
Riga
Country [26] 0 0
Lithuania
State/province [26] 0 0
Kaunas
Country [27] 0 0
Lithuania
State/province [27] 0 0
Utena
Country [28] 0 0
Lithuania
State/province [28] 0 0
Vilnius
Country [29] 0 0
Mexico
State/province [29] 0 0
Nuevo León
Country [30] 0 0
Mexico
State/province [30] 0 0
Chihuahua
Country [31] 0 0
Mexico
State/province [31] 0 0
Mexico city
Country [32] 0 0
Mexico
State/province [32] 0 0
Mexico
Country [33] 0 0
Peru
State/province [33] 0 0
Lima
Country [34] 0 0
Poland
State/province [34] 0 0
Lodz
Country [35] 0 0
Poland
State/province [35] 0 0
Rabka
Country [36] 0 0
Russian Federation
State/province [36] 0 0
Moscow
Country [37] 0 0
Russian Federation
State/province [37] 0 0
Novosibirsk
Country [38] 0 0
Russian Federation
State/province [38] 0 0
St'Petersburg
Country [39] 0 0
Russian Federation
State/province [39] 0 0
Tomsk
Country [40] 0 0
Spain
State/province [40] 0 0
Murcia
Country [41] 0 0
Spain
State/province [41] 0 0
San Javier (Murcia)

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is to assess the safety of an investigational drug in children 4 to 11 years of
age who have asthma. The subjects will attend 7 clinic visits, of which up to 3 will be in
the morning, and have lung function tests performed.
Trial website
https://clinicaltrials.gov/show/NCT00441441
Trial related presentations / publications
Li JS, Qaqundah PY, Weinstein SF, LaForce CF, Ellsworth AV, Ortega HG, Ferro TJ. Fluticasone propionate/salmeterol combination in children with asthma: key cardiac and overall safety results. Clin Res Reg Affairs 2010;27(3):87-95.
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications